Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 6/20 | 0.35 |
| ▸ | CCND1 | P24385 | 6/20 | 0.35 |
| ▸ | CCNE2 | O96020 | 5/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.34 |
| ▸ | CDK2 | P24941 | 5/20 | 0.34 |
| ▸ | PRKCI | P41743 | 1/20 | 0.32 |
| ▸ | PRKACA | P17612 | 1/20 | 0.32 |
| ▸ | PRKACG | P22612 | 1/20 | 0.32 |
| ▸ | PRKACB | P22694 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.30 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6030519 | 0.80 | KDM4E (0.38) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL16983161 | 0.78 | CDK4 (0.38) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL6030299 | 0.78 | PRKCI (0.33) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL24375839 | 0.77 | PRKCI (0.40) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL15712762 | 0.77 | PRKCI (0.48) | PRKCICYP2A6PIK3CB | |
| SCHEMBL29234948 | 0.77 | ESR1 (0.34) | CDK4CCND1PRKCIPRKACAPRKACG | |
| SCHEMBL6029602 | 0.76 | MTNR1A (0.36) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL29256160 | 0.74 | CDK4 (0.41) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL17661900 | 0.74 | GABRA1 (0.42) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL14745740 | 0.73 | NR3C1 (0.30) | PRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4712969-A1 | CYCLIN INHIBITORS | Circle Pharma, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20240408169-A1 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. | 2024-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240408169-A1 | CYCLIN INHIBITORS | CCNI, CDK2, CDK1 | CDK4 7/4885CCND1 36/4885CCNE2 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.